Month: March 2020

Investors are still waiting for next-generation biotech to deliver on its enormous promise and potential, but just one of these Holy Grails would make the wait worth it.

 Biotechnology has come a long way since 1978, when Herbert Boyer successfully demonstrated that human insulin could be produced from bacteria engineered with recombinant DNA. The breakthrough technology pushed a little-known company called Genentech into the spotlight and forever changed the world. Genentech was acquired by Roche for $46.8 billion in 2009. The American bioeconomy — biotech crops, biochemicals, and biologic drugs — generated an estimated $324 billion of gross domestic product in 2012. And millions of people worldwide today rely on insulin and other biologic drugs daily.

You could argue that recombinant DNA was the first Holy Grail technology delivered by the field. Several more have followed. In fact, we’ve recently been treated to the development and ongoing commercialization of the gene-editing technology known as CRISPR — a true game-changer for the biotech ecosystem. Headache-inducing legal entanglements aside, CRISPR promises to help synthetic biology deliver on its enormous potential and could even be an integral tool needed to produce several other world-changing Holy Grails. Some are closer to reality than investors may think.

Continue reading… “5 incredible synthetic biology holy grails that could change the world”